Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Available (expanded access)

Conditions studied: Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB)

In brief

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Key facts

Study ID

NCT04710056

Run by

Regeneron Pharmaceuticals

Last updated by the study team

2026-03-12

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.